|
FY2025
12 months to Dec 31, 2025
|
FY2024
5 months to Dec 31, 2024
|
|
|---|---|---|
| Revenue | ||
| Cost of revenue and operating expenses: | ||
| Cost of revenue | ||
| Research and development | ||
| Selling, general, and administrative | ||
| Impairment - Goodwill | ||
| Impairment - Intangibles assets, net | ||
| Total cost of revenue and operating expenses | ||
| Loss from operations | ||
| Other (expense) income: | ||
| Convertible notes fair value adjustment | ||
| Warrant liabilities fair value adjustment | ||
| Fair value measurement adjustments | ||
| Convertible notes | ||
| Common stock warrants | ||
| Interest expense | ||
| Interest income | ||
| Other (expense) income, net | ||
| Total other (loss) income, net | ||
| Net loss | ||
| Other comprehensive loss: | ||
| Foreign currency translation adjustment | ||
| Comprehensive loss | ||
| Basic net loss per share (in dollars per share) | ||
| Diluted net loss per share (in dollars per share) | ||
| Weighted-average shares outstanding - Basic (in shares) | ||
| Weighted-average shares outstanding - Diluted (in shares) |
Loading...
